The Globe and Mail reports in its Thursday, June 26, edition that TD Cowen analyst Vince Valentini thinks Telus Health is "becoming a high growth asset of consequence" for Telus Corp. ahead of an expected spinoff, with an initial public offering anticipated as early as 2026. The Globe's David Leeder writes in the Eye On Equities column that Mr. Valentini has reaffirmed his "buy" recommendation and $25 share target for Telus Corp. Analysts on average target the shares at $22.76. Mr. Valentini says in a note: "We expect Telus to sustain healthy dividend growth over the next three years. This growth, combined with the current yield, should drive outsized investor interest in Telus relative to BCE. Telus's yield and dividend growth stack up well versus Canadian alternatives, along with global telcos. Meanwhile, Telus's dividend quality is reasonable as we forecast it is set to drive its payout ratio to just below 100 per cent by FY26E. Additional non-core asset sales will also help its leverage and payout ratio quality. Telus has virtually completed the capital-intensive copper-to-fibre migration across its footprint. This will help it reduce costs through the decommissioning of its legacy copper network."